Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

6(75.0%)

Phase 3

2(25.0%)

8Total

Phase 1(6)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04845321Phase 1Terminated

VNRX-9945 Safety and Pharmacokinetics in Healthy Adult Volunteers

Role: lead

NCT06168734Phase 3Withdrawn

Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP

Role: lead

NCT04951505Phase 1Completed

Safety and Intrapulmonary Pharmacokinetics of Cefepime and Taniborbactam in Healthy Subjects

Role: lead

NCT03840148Phase 3Completed

Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections

Role: lead

NCT03870490Phase 1Completed

Safety and Pharmacokinetics of VNRX-5133 in the Epithelial Lining Fluid of Healthy Adult Subjects

Role: lead

NCT03690362Phase 1Completed

VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment

Role: lead

NCT03332732Phase 1Completed

VNRX-5133 Drug-Drug Interaction in Healthy Adult Volunteers

Role: lead

NCT02955459Phase 1Completed

VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers

Role: lead

All 8 trials loaded